158 related articles for article (PubMed ID: 22075465)
1. [Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer].
Koyama N; Tokunaga T; Ogasawara W; Murakami M; Yamashita Y
Nihon Yakurigaku Zasshi; 2011 Nov; 138(5):209-17. PubMed ID: 22075465
[No Abstract] [Full Text] [Related]
2. Eribulin mesylate (Halaven) for breast cancer.
Med Lett Drugs Ther; 2011 Apr; 53(1362):30-1. PubMed ID: 21502935
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
O'Shaughnessy J; Kaklamani V; Kalinsky K
Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
[TBL] [Abstract][Full Text] [Related]
4. Eribulin mesylate for the treatment of late-stage breast cancer.
Gourmelon C; Frenel JS; Campone M
Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
[TBL] [Abstract][Full Text] [Related]
5. Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
Leo S; Arnoldi E; Repetto L; Coccorullo Z; Cinieri S; Fedele P; Cazzaniga M; Lorusso V; Latorre A; Campanella G; Ciccarese M; Accettura C; Pisconti S; Rinaldi A; Brunetti C; Raffaele M; Coltelli L; Spazzapan S; Fratino L; Petrucelli L; Biganzoli L
Oncologist; 2019 Jun; 24(6):e232-e240. PubMed ID: 30413667
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
[TBL] [Abstract][Full Text] [Related]
7. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
Polastro L; Aftimos PG; Awada A
Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
[TBL] [Abstract][Full Text] [Related]
8. The safety of eribulin for the treatment of metastatic breast cancer.
Perez-Garcia JM; Cortes J
Expert Opin Drug Saf; 2019 May; 18(5):347-355. PubMed ID: 31107111
[No Abstract] [Full Text] [Related]
9. Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer.
de Nonneville A; Sabatier R; Gonçalves A; Extra JM; Tarpin C; Launay S; Tassy L; Viens P; Rousseau F
J Geriatr Oncol; 2018 May; 9(3):281-283. PubMed ID: 29174186
[No Abstract] [Full Text] [Related]
10. Advances in therapy: eribulin improves survival for metastatic breast cancer.
Morris PG
Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
[TBL] [Abstract][Full Text] [Related]
11. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
[TBL] [Abstract][Full Text] [Related]
12. Eribulin: rediscovering tubulin as an anticancer target.
Jimeno A
Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144
[TBL] [Abstract][Full Text] [Related]
13. A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden.
Kessler L; Falato C; Margolin S; Bergh J; Foukakis T
Acta Oncol; 2015 Apr; 54(4):522-9. PubMed ID: 25383448
[TBL] [Abstract][Full Text] [Related]
14. Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?
Aftimos P; Awada A
Adv Ther; 2011 Nov; 28(11):973-85. PubMed ID: 22020735
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
O'Sullivan Coyne G; Walsh J; Kelly CM
Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
Emambux S; Italiano A
Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
[TBL] [Abstract][Full Text] [Related]
19. Eribulin mesylate.
Jain S; Vahdat LT
Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
[TBL] [Abstract][Full Text] [Related]
20. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
McBride A; Butler SK
Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
